Evidence map›Paper›PMID 42801348›Full record

ReviewMolecular biology reports2026

Empowering cancer therapy: the promise of natural adjuvants.

Title De, Roshni Bibi, Koustav Sarkar

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Title DeDepartment of Biotechnology, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur, Tamil Nadu, 603203, India.ORCID http://orcid.org/0009-0008-0374-6584
Roshni BibiDepartment of Biotechnology, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur, Tamil Nadu, 603203, India.ORCID http://orcid.org/0009-0008-5616-4238
Koustav SarkarDepartment of Biotechnology, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur, Tamil Nadu, 603203, India. koustavsarkar@gmail.com.ORCID http://orcid.org/0000-0002-0696-6688

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer has consistently ranked as one of the major causes of mortality for numerous decades. Approximately 1 in 9 men and 1 in 12 women die from cancer-related deaths worldwide. Despite the development of numerous novel tactics and treatments, many of them have harmful side effects. As a result, there is a growing demand for products that are extracted or driven by natural processes as powerful anti-cancer agents due to their potential biological activities and various structural diversities; however, their chemical inertness and safety should be evaluated and standardized. Naturally extracted adjuvants are biologically derived substances that can enhance or modulate the immune response, including antigens, and may support cancer immunotherapeutic strategies. Furthermore, a natural adjuvant can promote the activation and maturation of the antigen-presenting cells (APCs), hence enhancing antigen presentation and processing linked to the major histocompatibility complex (MHC). Ultimately, stimulating the signaling pathways to regulate cytokine production and T-cell activation. Therefore, they are potential candidates in the management of cancers of the breast, melanoma, liver, and prostate, although there are variations in the supporting evidence among different subjects and cancer types. Depending on their formulations, natural adjuvants may be used as a component of drug or antigen-delivery systems, or can be incorporated into vaccine production. This review seeks to encapsulate the comprehensive activity of natural immunomodulators extracted from plants, microorganisms, and animals to exhibit adjuvant activity, and therefore emphasizes their immunological mechanisms and incorporation into cancer immunotherapy and related strategies.

Indexed as

Adjuvants, ImmunologicBiological ProductsNeoplasmsAnimalsAntigen PresentationAntigen-Presenting CellsHumansImmunotherapyAdjuvants, ImmunologicBiological ProductsAntigen-presenting cells (APCs)Cytotoxic T lymphocytes (CTLs)Dendritic cells (DCs)Major histocompatibility complex (MHC)

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.